Association between KIR3DS1, KIR3DL1, and HLA-Bw4
| Patient group . | Median PFS, mo (95%CI) . | No. . | P . |
|---|---|---|---|
| All patients regardless of disease status at ASCT | .042 | ||
| KIR3DS1+/KIR3DL1+HLA-Bw4− | 13.2 (10-16) | 26 | |
| KIR3DS1+/KIR3DL1+HLA-Bw4+ | 16.7 (13-21) | 22 | |
| KIR3DS1−/KIR3DL1+ | 20.4 (18-23) | 119 | |
| Good risk patients | .002 | ||
| Good risk KIR3DS1+/KIR3DL1+HLA-Bw4− | 12.2 (11.9-12.6) | 19 | |
| Good risk KIR3DS1+/KIR3DL1+HLA-Bw4+ | 16.7 (12-21) | 21 | |
| Good risk KIR3DS1−/KIR3DL1+ | 24 (19.7-28) | 100 |
| Patient group . | Median PFS, mo (95%CI) . | No. . | P . |
|---|---|---|---|
| All patients regardless of disease status at ASCT | .042 | ||
| KIR3DS1+/KIR3DL1+HLA-Bw4− | 13.2 (10-16) | 26 | |
| KIR3DS1+/KIR3DL1+HLA-Bw4+ | 16.7 (13-21) | 22 | |
| KIR3DS1−/KIR3DL1+ | 20.4 (18-23) | 119 | |
| Good risk patients | .002 | ||
| Good risk KIR3DS1+/KIR3DL1+HLA-Bw4− | 12.2 (11.9-12.6) | 19 | |
| Good risk KIR3DS1+/KIR3DL1+HLA-Bw4+ | 16.7 (12-21) | 21 | |
| Good risk KIR3DS1−/KIR3DL1+ | 24 (19.7-28) | 100 |
Patients were divided into three groups: (1) KIR3DS1+/KIR3DL1+HLA-Bw4−, (2) KIR3DS1+/KIR3DL1 HLA-Bw4−, and (3) KIR3DS1−/KIR3DL1+.
PFS indicates progression-free survival; and ASCT, autologous stem cell transplantation.